In September 2022, Shanghai Municipal Science and Technology Commission announced the projects for Shanghai 2022 Technology-based SME Technology Innovation Fund Program. After a strict selection and tough competition by the Expert Committee of Shanghai Municipal Science and Technology Commission, Shanghai Leadingtac Pharmaceutical Co., Ltd. declared "Protein Degrader innovative drug LT002 preclinical study".

The Technology Innovation Fund for Small and Medium-sized Enterprises (SMEs) is a unique funding program established by the Shanghai Municipal Science and Technology Commission according to the "Shanghai Technology Innovation Fund for Small and Medium-sized Enterprises Program Management Measures" for SMEs. This innovation fund aims to promote the implementation of an innovation-driven development strategy, improve the efficiency of science and technology innovation, encourage "mass entrepreneurship and innovation", promote the technological innovation activities of science and technology-based SMEs in Shanghai, and accelerate the construction of a globally influential science and technology innovation center.

About Leadingtac

Shanghai Leadingtac Pharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to developing First-in-class/Best-in-class small molecule innovative drugs. With a platform of Targeted Protein Degradation (TPD) drugs, Leadingtac focuses on two therapeutic areas with critical commercial potential and synergies, autoimmunity and oncology, to provide breakthrough therapeutic solutions for patients.

The company's founder studied at leading U.S. universities and served as executives in leading multinational pharmaceutical companies and CROs, advancing several small molecule drugs to clinical trials, and has extensive experience in developing small molecule innovative drugs. Based on previous R&D operations and different strategies, the company's R&D team has established a nano-SPUD innovative drug development and screening platform with a focus on targeted protein degradation. Within three years since its establishment, the company has successfully applied for 11 patents, 9 of which have been submitted to PCT. Currently, the company has developed several product pipelines using cutting-edge technologies such as Protein Degrader and LYTAC, and has identified one preclinical candidate compound (PCC) through its in-house screening platform, and will submit the first clinical trial application for the first pipeline in the Q1 of 2023 in China, U.S., and Australia ( IND). This pipeline is currently the first in China and the second in the world. In addition, the preclinical candidate compound (PCC) for the second pipeline (First-in-class) has also been extensively selected, which will be the first in the world.